INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

Future Oncol. 2024 May;20(14):935-950. doi: 10.2217/fon-2023-0604. Epub 2024 Jan 10.

Abstract

Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.

Keywords: IRd; effectiveness; ixazomib; ixazomib-lenalidomide-dexamethasone; multiple myeloma; pooled analysis; progression-free survival; proteasome inhibitor; relapsed/refractory; routine clinical practice; time-to-next treatment.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boron Compounds / therapeutic use
  • Dexamethasone / therapeutic use
  • Glycine* / analogs & derivatives
  • Humans
  • Lenalidomide / therapeutic use
  • Multicenter Studies as Topic
  • Multiple Myeloma* / drug therapy
  • Prospective Studies
  • Retrospective Studies

Substances

  • Boron Compounds
  • Dexamethasone
  • Glycine
  • ixazomib
  • Lenalidomide